This week in drug discovery (16-20 May)    

News round-up by DDW’s Reece Armstrong for 16-20 May 

Drug approvals, a focus on Covid-19 and collaborative milestones are some of the themes of this week’s news round-up.  

MHRA approves Eli Lilly’s breast cancer oral inhibitor   

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to Eli Lilly’s oral inhibitor abemaciclib for the treatment of patients with a specific type of breast cancer.   

NIAID to establish research centres to combat future pandemics   

The National Institute of Allergy and Infectious Diseases (NIAID) is investing $577 million to establish nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern, the organisation has announced.   

BenevolentAI achieves third milestone with AstraZeneca 

AstraZeneca has identified an additional target for its idiopathic pulmonary fibrosis (IPF) pipeline using an AI system designed by drug discovery company BenevolentAI. 

Biotechs partner to understand genetics of long Covid    

A partnership between life sciences companies PrecisionLife and Sano Genetics aims to drive insights into the genetics of long Covid and potentially identify new treatments.  

Boehringer Ingelheim reports positive data for lung therapy   

Boehringer Ingelheim’s investigational therapy for idiopathic pulmonary fibrosis (IPF) has shown positive data in a Phase II clinical trial, the company has announced. 


Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free